Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People presenting for the first time with operable breast cancer, with no previous treatment for any invasive cancer (male or female).
• People whose primary breast tumor is larger than 2 cm in diameter.
• People aged 18 years or older and under 70 years of age.
• People with a general health/activity level rated at 0 or 1 on a standard medical scale, meaning they are fully active or restricted in strenuous activity but able to carry out light work (confirm with trial site).
• People whose heart pumping function (left ventricular ejection fraction) is measured at 55% or above.
• People for whom a tumor tissue sample will be available after surgery.
• People who agree to have a needle biopsy taken for genetic testing and a laboratory drug sensitivity test.
• People whose breast cancer has been confirmed through tissue examination under a microscope.
• People whose cancer tests positive for a protein called HER2, either by a specific staining test (IHC 3+) or by a gene amplification test (FISH).
• People who have had their hormone receptor status (ER and PgR) tested.
• People who have signed a consent form agreeing to take part.
• People who are able to follow the requirements of the trial protocol.

Who may not be able to join:

• People whose cancer has spread to other parts of the body (Stage IV), or who have cancer in both breasts.
• People who have previously received any systemic cancer treatment, including chemotherapy, immunotherapy, HER2-targeted therapy, or cancer vaccines, or who have had radiation therapy for cancer.
• People who have had a previous breast or any other cancer diagnosis within the past 5 years.
• People with poor bone marrow, kidney, or liver function.
• People with a history of or current heart or cardiovascular condition.
• People with a severe or uncontrolled illness affecting the whole body.
• People with poorly managed diabetes or signs of serious diabetes-related complications affecting blood vessels.
• People who are pregnant or breastfeeding.
• People who received any experimental treatment within 4 weeks before the trial start date.
• People with a known infection with HIV, hepatitis B, or hepatitis C.
• People currently taking corticosteroid tablets daily at a dose higher than 10 mg of methylprednisolone or an equivalent dose (not including inhaled steroids).
• People with a known allergy or sensitivity to any of the medications or ingredients used in the trial.

Important: Always verify eligibility with the trial site directly before applying.